cis-N¹-methylcyclohexane-1,3-diamine

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: cis-N¹-methylcyclohexane-1,3-diamine
• 英文别名: rel-N1-Methylcyclohexane-1,3-diamine；(1R,3S)-1-N-methylcyclohexane-1,3-diamine
• 化学式: C₇H₁₆N₂
• 分子量: 128.217
• InChiKey: VSZFBKJHIUYKMK-NKWVEPMBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  38
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  benzyl cis-(3-(((benzyloxy)carbonyl)amino)cyclohexyl)(methyl)carbamate 在 甲醇 、 palladium on activated charcoal 作用下， 反应 2.0h， 以77.3%的产率得到cis-N¹-methylcyclohexane-1,3-diamine
  参考文献：
  名称：

  [EN] PYRIMIDYL DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF
  [FR] DÉRIVÉ DE PYRIMIDYLE, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION
  [ZH] 嘧啶基衍生物、其制备方法及其用途

  摘要：

  一种嘧啶基衍生物、其制备方法及其用途。所述嘧啶基衍生物具有通式(I)所示结构。该嘧啶基衍生物可以作为具有选择性的CDK7抑制剂，解决多种癌症的有效治疗需求，尤其是转录失调的癌症。

  公开号：

  WO2022063212A1

文献信息

• INHIBITORS OF INFLUENZA VIRUSES REPLICATION
  申请人：Vertex Pharmaceuticals Inc.

  公开号：EP3141252A1

  公开（公告）日：2017-03-15

  Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A compound is represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

  抑制生物样本或患者体内流感病毒复制、减少生物样本或患者体内流感病毒数量以及治疗患者流感的方法，包括向所述生物样本或患者施用有效量的结构式（I）所代表的化合物： 或其药学上可接受的盐，其中结构式（IA）的值如本文所述。一种化合物由结构式（IA）或其药学上可接受的盐代表，其中结构式（IA）的值如本文所述。药物组合物包含有效量的此类化合物或其药学上可接受的盐，以及药学上可接受的载体、佐剂或载体。
• Aryl substituted pyrimidines for use in influenza virus infection
  申请人：Janssen Sciences Ireland UC

  公开号：US10611755B2

  公开（公告）日：2020-04-07

  The invention relates to compounds having the structure of formula (I) which can be used for the treatment of or against influenza infections.

  本发明涉及具有式（I）结构的化合物，可用于治疗或预防流感感染。
• ARYL SUBSTITUTED PYRIMIDINES FOR USE IN INFLUENZA VIRUS INFECTION
  申请人：Janssen Sciences Ireland UC

  公开号：US20190047989A1

  公开（公告）日：2019-02-14

  The invention relates to compounds having the structure of formula (I) which can be used for the treatment of or against influenza infections.
• ARYL SUBSTITUTED PYRIMIDINES FOR USE INFLUENZA VIRUS INFECTION
  申请人：Janssen Sciences Ireland Unlimited Company

  公开号：US20200231577A1

  公开（公告）日：2020-07-23

  The invention relates to compounds having the structure of formula (I) which can be used for the treatment of or against influenza infections.
• COMPOUNDS, COMPOSITIONS AND METHODS OF USE
  申请人：Aquinnah Pharmaceuticals, Inc.

  公开号：US20200270211A1

  公开（公告）日：2020-08-27

  Herein, compounds, compositions and methods for modulating inclusion formation and stress granules in cells related to the onset of neurodegenerative diseases, musculoskeletal diseases, cancer, ophthalmological diseases, and viral infections are described.